Why it matters
The findings could matter to U.S. patients with this aggressive cancer and to clinicians evaluating treatment options, but they do not establish that the combination is available or approved for this use.
RESEARCH & TREATMENTS • UNITED STATES
Amgen reports 58% lower death risk with lung cancer drug combination
This brief summarizes public reporting and official announcements. Research findings may be preliminary. Talk to a qualified clinician before making health decisions.
This event has left the current brief. The summary below describes the stored record; open the original sources for current conditions.
BLUF
Amgen says adding tarlatamab to an AstraZeneca immunotherapy cut the risk of death by 58% in patients with extensive-stage small-cell lung cancer. MedPage Today reports a large randomized trial found median survival approached two years; the supplied reports do not establish whether this combination is approved.
HOW THIS BRIEF WAS MADE 2 outlets: 1 national · 1 specialist. Automated sourcing and summaries by the BLUF engine. Corrections